Sudha, ThangiralaLin, ThangiralaElmetwally, Ahmed M.Nazeer, TipuArumugam, ThiruvengadamPhillips, Patricia G.Mousa, Shaker A.2022-07-042022-07-042014-08-01Sudha, T. vd. (2014). "Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin". Cancer Letters, 350(1-2), 25-33.0304-38351872-7980https://doi.org/10.1016/j.canlet.2014.04.016https://www.sciencedirect.com/science/article/pii/S0304383514002237http://hdl.handle.net/11452/27639Sulfated non-anticoagulant heparins (S-NACHs) might be preferred for potential clinical use in cancer patients without affecting hemostasis as compared to low molecular weight heparins (LMWHs). We investigated anti-tumor effects, anti-angiogenesis effects, and mechanisms of S-NACH in a mouse model of pancreatic cancer as compared to the LMWH tinzaparin. S-NACH or tinzaparin with or without gemcitabine were administered, and tumor luminescent signal intensity, tumor weight, and histopathology were assessed at the termination of the study. S-NACH and LMWH efficiently inhibited tumor growth and metastasis, without any observed bleeding events with S-NACH as compared to tinzaparin. S-NACH distinctly increased tumor necrosis and enhanced gemcitabine response in the mouse pancreatic cancer models. These data suggest the potential implication of S-NACH as a neoadjuvant in pancreatic cancer.eninfo:eu-repo/semantics/openAccessLow molecular weight heparinPancreatic cancerNon-anticoagulant heparinAnti-cancerTumor suppressorTumor survivalFactor pathway inhibitorTumor-growthP-selectionSurvivalAngiogenesisMetastasisEnoxaparinResistanceThrombosisInvasionOncologyAngiogenesis inhibitorsAnimalsCell line, tumorChick embryoChorioallantoic membraneDeoxycytidineEnzyme inhibitorsFemaleFibrinolytic agentsHeparin, low-molecular-weightHumansMiceMice, nudeNeoplasm metastasisNeovascularization, pathologicPancreatic neoplasmsXenograft model antitumor assaysArticle0003378710000042-s2.0-8490149431925333501-224769074OncologyVenous Thromboembolism; Cancer; Anticoagulant AgentAntineoplastic agentGemcitabineLow molecular weight heparinSulfated non anticoagulant heparinTinzaparinUnclassified drugAnimal experimentAnimal modelAnimal tissueAntiangiogenic activityAntineoplastic activityArticleBleedingCancer inhibitionControlled studyDrug mechanismDrug responseDrug sulfationFemaleHistopathologyHumanHuman cellLuminescenceMetastasis inhibitionMouseNonhumanPancreas cancerPriority journalTumor necrosis